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KEY POINTS
 Malignant peripheral nerve sheath tumors (MPNST) are the sixth most frequent soft tissue sarcoma
(STS), consisting of 5% to 10% of cases.
 Traditionally, MR imaging has been the main imaging modality to evaluate the extent and involve-
ment of MPNT.
 The potential value of PET and PET/CT in regards to diagnosis, biopsy guidance, staging, and ther-
apy response of MPNT are presented in the literature.
 Multimodality imaging with multiparametric hybrid PET/MR has also shown some utility in the man-
agement of peripheral nerve tumors (PNTs).
 Quantitative FDG-PET imaging used in combination with CT or MR imaging has shown great poten-
tial to discriminate benign from malignant PNTs.INTRODUCTION
Peripheral nerve tumors (PNT) are a heteroge-
neous category of neoplasms that are very rare
in the population. The classification of theses tu-
mors is variable, as most of these tumors have
more than one name. Furthermore, peripheral
nerve sheath tumors encompass a variety of cell
types, some of which are not yet completely char-
acterized. Common classification systems are
based on the presence or absence of neoplasia,
whether the neoplasm is benign or malignant,
and the cellular origin of the primary neoplasia.1,2
Malignant peripheral nerve sheath tumors
(MPNST) are the sixth most frequent soft tissue
sarcoma (STS), consisting of 5% to 10% of
cases.3–5 Approximately 50% of all MPNST
develop sporadically, whereas the other 50%
are associated with neurofibromatosis type 1a Department of Molecular Imaging and Radionuclide
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lifetime risk of developing MPNST, with an inci-
dence of 1:3500, compared with the incidence of
1:100,000 among the general population.6
Approximately 30% of NF1-associated MPNST
arise from a deeply located neurofibroma, with
most of the tumors developing in the proximal up-
per and lower limbs.9 Patients can present with a
variety of symptoms, which may include pain,
paresthesia, and neurologic deficits.10 MPNST
have a poor prognosis, with overall 5-year survival
rates ranging from 20% to 50% for high-grade
MPNST and a mortality of up to 75%.11
Diagnostic imaging of PNT is crucial for proper
characterization and management. Traditionally,
MR imaging has been the main imaging modality
to evaluate the extent and involvement of PNT.
Ultrasound and computed tomography (CT) can
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Assadi et al2used for image-guided biopsies.12 Furthermore,
bone scintigraphy may be useful to evaluate for
osseous involvement.13
Over recent years, PET has been gaining
increasing traction in the assessment of musculo-
skeletal tumors. The use of PET to assess disease
biology at an individual level is now playing a
pivotal role in personalized clinical decision mak-
ing and further clinical management.14–16 How-
ever, although the use of PET/CT is being
increasingly used in patients with MPNST, its def-
inite role within the clinical routine is still not delin-
eated, partially because of the rarity of these
tumors hindering prospective investigations with
large patient groups. Here, the authors discuss
the role and potential value of PET and PET/CT
in regards to diagnosis, biopsy guidance, staging,
and therapy response of PNT.DIAGNOSIS AND DIFFERENTIATION BETWEEN
BENIGN AND MALIGNANT PERIPHERAL
NERVE TUMORS WITH
FLUDEOXYGLUCOSE-PET
The diagnosis of MPNST and their distinction
from benign tumors remain a clinical challenge,
because the symptoms of the 2 conditions
demonstrate substantial overlap. At present, CT,
MR imaging, and PET are the main imaging tools
used to assess and diagnose MPNST. Both CT
and MR imaging are useful to define the anatomic
tumor size and local invasiveness of MPNST.17 In
addition, several investigations have developed
diagnostic criteria to help aid in the discrimination
between benign and malignant PNT using CT and
MR imaging. However, these criteria have not
been reliable in distinguishing between benign
and malignant PNTs, especially when tumors are
inhomogeneous.18 Thus, the main shortcoming
of both CT and MR imaging is the inability to
efficiently confirm malignant transformation of
lesions.17
To address this issue, several studies have
assessed the ability of fludeoxyglucose (FDG)-
PET with or without CT to distinguish benign
from malignant primary PNT based on a tumor’s
metabolic activity.17,19–22 In general, benign
PNTs depict no or low FDG uptake, whereas ma-
lignant PNTs demonstrate moderate to high FDG
accumulation. In these studies, standard uptake
values (SUV), a quantitative amount of FDG up-
take, range between 1.0 and 3.99 in benign
PNTs and between 3.1 and 21.4 in malignant
PNTs.17,23–26 In a systematic review by Tovmas-
sian and colleagues,19 summarizing 796 tumors
from 13 various reports, FDG-PET demonstrated
noteworthy difference regarding the distinction ofbenign from malignant PNTs (mean SUVmax:
1.93 vs 7.48) with a mean accuracy across the
studies of 83.5%. Receiver operating character-
istic analysis was carried out in several of the
studies to determine optimal SUVmax cutoff.
These values yielded cutoffs of 3.1, 3.2, 3.5, 4.1,
and 6.1 to attain maximum statistical parameters
of ascertaining malignant lesions.19 It revealed
that FDG-PET/CT could be valuable in the diag-
nosis of malignant lesions with the sensitivities
ranging from 91% to 100% and specificity ranging
from 72% to 95%. However, there was significant
overlap in ranges of SUVmax in these studies and
inadequate evidence to admit a universal cutoff
value for SUVmax (Fig. 1).19
Recently, Azizi and colleagues27 evaluated the
value of FDG-PET imaging in the detection of ma-
lignant transformation of symptomatic and asymp-
tomatic plexiform neurofibromas in 41 children
with NF1. This study demonstrated overlap
between the SUVmax of malignant and benign le-
sions, yet no malignant lesion demonstrated FDG
uptake less than 3.15 (Fig. 2). Asymptomatic ma-
lignant lesions were diagnosed with a sensitivity
of 100%, a negative predictive value of 100%,
and a specificity of 45.1%. This value highlights
the utility of FDG-PET in detecting malignant trans-
formation of plexiform neurofibromas, especially in
asymptomatic patients. This issue may reveal
MPNST at early stages, potentially increasing the
possibility of oncologically curative resections.
Dual-time-point FDG-PET has demonstrated
some potential in distinction between malignant
and nonmalignant PNTs.23,28 However, PNTs
have mostly shown similar FDG uptake on delayed
projection, and the implication of this protocol re-
mains unknown.26 Multimodality imaging with mul-
tiparametric hybrid PET/MR has also shown some
utility in the management of PNTs.29,30 A few
studies have assessed the combined use of
FDG-PET and MR imaging in this regard.24,31,32
Broski and colleagues31 carried out the largest
study to date assessing the performance of
FDG-PET and MR imaging in a cohort of histolog-
ically proven benign and malignant peripheral
nerve sheath tumors involving 38 patients with 23
benign PNSTs and 20 malignant PNSTs. In this
study, FDG PET was 90% to 100% sensitive and
52.2% to 82.6% specific for diagnosing MPNST,
whereas expertly interpreted MR images had a
62.5% to 81.3% sensitivity and 94.1% to 100%
specificity, thus underscoring the complementary
role of PET/MR imaging in the management of
PNTs. In addition, as state-of-the-art PET/MR im-
aging becomes more common, concurrent com-
bined PET and MR imaging offers the potential of
a “one-stop-shop” imaging modality for patients.
Fig. 1. A 70-year-old woman who initially presented with left paraspinal and lower extremity pain. Axial T1 (A)
and T1 FS postcontrast (B) MR images demonstrate a 4.8-cm mass (arrows) centered in the left S1 neural foramen.
18F-FDG PET/CT (C) shows intense hypermetabolism with SUVmax of 8.9 (arrow). CT-guided biopsy (D) and sub-
sequent resection (arrow) both came back as benign schwannoma despite the high SUVmax.
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benign and malignant PNTs remains a challenge.
Quantitative FDG-PET imaging used in combina-
tion with CT or MR imaging has shown great
potential to discriminate benign from malignant
PNTs. Nevertheless, additional studies are
needed, and the imaging and clinical character-
istics of PNTs have not yet replaced histopatho-
logic consideration as the gold standard for
diagnosis.GRADING OF MALIGNANT PERIPHERAL
NERVE SHEATH TUMORS WITH
FLUDEOXYGLUCOSE-PET
Accurate histologic grading is imperative in the
assessment and management of MPNST. Preop-
erative imaging appraisal of the histologic grade
is a challenging subject, with several contradicting
results between FDG uptake (SUVmax) and histo-
pathologic grading of MPNST.
In a study by Ferner and colleagues,28 assessing
FDG-PET/CT as a diagnostic modality for MPNST
in NF1 cases with symptomatic plexiform neurofi-
bromas, a total of 116 lesions were evaluated in105 patients, including 80 plexiform neurofi-
bromas, 5 atypical neurofibromas, 29 MPNST,
and 2 other tumors. FDG-PET and PET/CT
detected NF1-associated tumors with a sensitivity
of 0.89 (95% confidence interval [CI] 0.76 to 0.96)
and a specificity of 0.95 (CI 0.88–0.98); however,
the SUVmax level did not predict tumor grade.
Kim and colleagues33 retrospectively investigated
CT (n 5 14), MR imaging (n 5 16), and 18F-FDG
PET/CT (n 5 5) imaging characteristics of 18
different MPNST of the head and neck in 17 pa-
tients. 18F-FDG PET/CT images acquired for 5
cases depicted homogeneous (n5 3) or heteroge-
neous (n 5 2) hypermetabolic foci with a mean
SUVmax of 7.16  4.57 (range, 3.2–14.6). In this
study, the SUVmax correlated well with the histo-
logic grade of the tumors: 2 with SUVmax of 3.2
and 3.9 were histologically categorized as low
grade; one with SUVmax of 6.1 as intermediate
grade; and 2 with SUVmax of 8.0 and 14.6 as
high grade (Fig. 3). Warbey and colleagues23
assessed 69 patients with NF1 with 85 lesions,
including 10 atypical neurofibromas and 21
MPNST. In this study, FDG-PET was very sensitive
(97%) and specific (87%) in the diagnosis of
Fig. 3. A 44-year-old man with history of left axillary malignant peripheral nerve sheath tumor, status postresec-
tion with positive margins and adjuvant radiation therapy. A recent biopsy of a left chest wall mass demonstrated
fibrosis on pathology. Axial noncontrast CT (A) demonstrates an ill-defined left chest wall periscapular mass (ar-
row). 18F-FDG PET/CT (B) shows intense hypermetabolism with SUVmax of 23.5 (arrow). Axial contrast-enhanced
CT (C) and axial STIR MR imaging (D) show heterogeneous enhancement and signal intensity within this recurrent
high-grade MPNST (arrows).
Fig. 2. A 24-year-old man with history of NF1. Coronal (A) and axial (B) 18F-FDG PET/CT and sagittal (C) and axial
(D) T2-weighted MR images demonstrate numerous paraspinal masses (arrows). The SUVmax was 3 or less for all
of these masses, indicating that these are all benign neurofibromas without need for further workup at this time.
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PET Imaging of Peripheral Nerve Tumors 5MPNST. Cardona and colleagues34 demonstrated
that MPNST have considerably higher FDG uptake
in their assessment of 25 neurogenic STS.
Furthermore, schwannomas should be included
in the differential diagnosis of peripheral nerve
sheath tumors with low, intermediate, or high
SUVs.35 Given the considerable overlap in the
SUVmax between low- and high-grade MPNST,
further studies using new tracers and parameters
may be helpful in discriminating high- and low-
grade MPNST.28,36
In summary, although higher-grade tumors are
typically more metabolically active than lower-
grade tumors, there is currently a lack of evidence
for the ability of FDG-PET to assess tumor grade in
PNTs. Further studies evaluating SUV parameters
and tumor grade of PNTs are needed, and bi-
opsies with histologic analysis should be routinely
performed to accurately ascertain tumor grade.BIOPSY GUIDANCE AND STAGING OF
MALIGNANT PERIPHERAL NERVE SHEATH
TUMORS WITH FLUDEOXYGLUCOSE-PET/
COMPUTED TOMOGRAPHY
The standard management of MPNST requires bi-
opsy before surgical resection. One way to
improve biopsy results is to leverage the metabolic
data afforded by PET imaging to efficiently target
and sample tissues, especially when other modal-
ities such as radiograph, CT, or ultrasound do not
clearly identify the abnormality. PET/CT-guided bi-
opsy combines the well-established worth of
anatomic information from CT with the metabolic
information from FDG-PET. In a study of 26 NF1
patients with a clinical suspicion of MPNST and
suspect lesion on PET/CT scan, Brahmi and col-
leagues37 demonstrated a diagnostic accuracy
rate of 96% with PET/CT-guided percutaneous bi-
opsies (Fig. 4).
The exact role of PET-guided biopsy is not yet
well established, but may be of most benefit inFig. 4. A 34-year-old female patient with history of NF1
neous hypermetabolism of the right pelvis mass (arrow) w
CT-guided biopsy (B) targeted the most hypermetabolic m
to be an MPNST.patients with previous inconclusive biopsy findings
or findings discordant with the overall clinical and
imaging data. Furthermore, large malignant le-
sions can be heterogeneous, and PET/CT func-
tional imaging-driven biopsy may be of great
benefit for guiding biopsies.38,39 Last, in the case
of local tumor recurrence, whereby it can be diffi-
cult to distinguish between posttreatment
changes and local recurrence, PET/CT-guided bi-
opsies may be of value.
Accurate staging of MPNST is important for
treatment planning and prognostic stratification.
It has been demonstrated that most MPNST are
high-grade sarcomas, with a high probability of
local recurrence and distant metastasis. In total,
40% to 65% of MPNST cases experience local
recurrence and 30% to 60% develop metasta-
ses.40–42 Approximately 65% of MPNST metasta-
ses are to the lungs, with the liver, brain, bones,
and adrenal glands also being common sites of
distant spread. Regional lymph node involvement
is infrequent, and for this reason, lymph node
dissection should not be regularly done.4
Overall, PET/CT has a noteworthy effect on
staging and restaging sarcomas particularly for
lymph nodal metastases, distant metastases,
and local relapse. Local recurrence can often
be difficult to distinguish from posttreatment
changes. In a study of 47 patients with MPNST,
Khiewvan and colleagues43 demonstrated 100%
sensitivity for PET/CT to detect locally recurrent
disease compared with 86% with conventional
CT imaging. Furthermore, the PET/CT scans
detected significantly more distant sites of dis-
ease, resulting in treatment changes in 31% of pa-
tients undergoing initial staging examinations.
However, the sensitivity has been shown to be
lower for lung metastases; thus, nodules found
on diagnostic CT should be suspect in the appro-
priate clinical setting, even in the absence of
increased metabolically activity. In conclusion,
PET/CT can more accurately stage and restageand pelvic mass. 18F-FDG PET/CT (A) shows heteroge-
ith an SUVmax of 12.3 and erosion of the right ilium.
edial aspect of the mass (arrow), which was diagnosed
Assadi et al6patients with PNT and may result in a paradigm
shift in patient management strategy.THERAPY RESPONSE ASSESSMENT AND
PROGNOSIS OF MALIGNANT PERIPHERAL
NERVE SHEATH TUMORS WITH
FLUDEOXYGLUCOSE-PET/COMPUTED
TOMOGRAPHY
The literature addressing the utility of FDG-PET/CT
for therapy response assessment andprognosis for
MPNST is scarce. At present, most STS cases,
particularly those with intermediate and high
grades, are treated with neoadjuvant chemo-
therapy or radiotherapy before surgical resection.44
Precise noninvasive evaluation of therapy response
would be of great value for STS treatment to better
guide therapeutic decisions and avoid ineffective
chemotherapy or radiation treatment. The RECIST
criteria for solid tumors have been shown to be inef-
fective for sarcoma treatment response evalua-
tion.45,46 This demerit is due to the fact that most
of these tumors encompass structural parts, hin-
dering tumor shrinkage after cytotoxic therapy.
Therefore, several reports have revealed thatmeta-
bolic imaging with FDG-PET/CT is superior to
morphologic imaging such as MR imaging or CT in
therapy response evaluation in STS.47–49
In patients with STS, it is imperative to identify
prognostic parameters to delineate the best man-
agement strategy and follow-up examinations.
Although factors such as large tumor size and in-
termediate- or high-grade histology are associ-
ated with reduced survival, numerous studies
have focused on the relation between tumor FDG
uptake and tumor necrosis, with higher levels of
tumor necrosis a strong predictor of long-term
therapy response.44,50–52
Moreover, as noted above, it is frequently prob-
lematic to diagnose local recurrence of STS due to
changes in the normal anatomy by prior manipula-
tions such as surgery or radiotherapy. Based on
the small number of reports regarding this issue,
PET imaging has demonstrated a high sensitivity
for the revealing of local recurrence in high-grade
STS, although diagnosis of recurrences of
low-grade tumors cannot be anticipated from
FDG-PET.43,53,54 Despite the potential implication
of FDG-PET/CT in the diagnosis of STS recur-
rence, the application of FDG-PET into the
follow-up strategy of STS patients is not yet well
characterized.NEW PARAMETERS AND RADIOTRACERS
Novel parameters such as metabolic tumor vol-
ume and total lesion glycolysis have been usedin prior studies with promising results.19,31,55,56
In addition, Derlin and colleagues24 have evalu-
ated the utility of the Homogeneity Index SUV,
incorporating the metabolic homogeneity of a
lesion, which has resulted in increasing speci-
ficity between benign and malignant lesions.
However, SUVmax remains the most supported
parameter in the literature, and further investiga-
tions into these novel parameters are required to
elucidate their clinical significance. In view of
multitracer PET imaging, it has been demon-
strated that intertumoral and intratumoral
heterogeneity of blood flow and angiogenesis,
hypoxia, necrosis, cellular proliferation, gene
mutation, and expression of specific receptors
can be evaluated with FDG and non-FDG-PET
radiotracers, potentially assisting in medical
decision making in the era of personalized
medicine.52,57,58
In a study of 22 patients with schwannomas,
Ahmed and colleagues59 compared 18F FDG-
PET to 18F-fluoro-a-methyl tyrosine (18FMT), an
amino acid tracer that monitors protein meta-
bolism, and concluded that 18FMT-PET is
more accurate for distinction between benign
schwannoma and malignancy than 18FDG-PET.
In addition, prostate-specific membrane antigen
(PSMA), a transmembrane glycoprotein primarily
expressed by prostate cells and other tissues
(eg, small intestine, renal tubules, or salivary
glands),60 was noted in the endothelium of
tumor-associated neovasculature in some solid
cancers such as MPNST, possibly due to the ef-
fect of tumor-associated angiogenic factors.61–64
Somatostatin receptor agonists such as DOTA-
TATE have also been proven to have valuable ef-
fects on the management of neuroendocrine can-
cers, indicating value for these radiotracers in the
clinical management of somatostatin-avid can-
cers,65 such as PNTs.66–69 Furthermore, PSMA
and DOTA-TATE also can be bound with radionu-
clides such as gallium-68 and lutetium-177 to
develop radiopharmaceuticals for both PET imag-
ing and radionuclide therapy.SUMMARY
In conclusion, FDG-PET, especially in conjunction
with CT, is a useful imaging modality for patients
with PNT with many advantages over conventional
imaging. This modality can aid in the diagnosis,
staging, and restaging of PNT as well as in
image-guided biopsy. Furthermore, FDG-PET
may serve a role in the grading of PNT and assist
in determining prognosis and treatment response,
although additional data are needed. The use of
FDG-PET/CT for PNT can significantly affect
PET Imaging of Peripheral Nerve Tumors 7clinical management and enables the implementa-
tion of precision medicine, an emerging theme for
future clinical practice. In addition, a growing body
of evidence supports the use of hybrid PET-MR
imaging and alternative radiotracers in PNT.
This overview provides insights into the useful-
ness of PET in peripheral nerve oncology
and how it can assist in providing optimal
patient care. However, additional studies evalu-
ating FDG-PET and the development of more
specific radiotracers are still needed to improve
the performance of PET in the assessment of
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